TY - JOUR
T1 - SCORE2 Report 20
T2 - Relationship of Treatment Discontinuation With Visual Acuity and Central Subfield Thickness Outcomes
AU - SCORE2 Investigator Group
AU - Scott, Ingrid U.
AU - Oden, Neal L.
AU - VanVeldhuisen, Paul C.
AU - Ip, Michael S.
AU - Blodi, Barbara A.
N1 - Funding Information:
Acknowledgement: Funding/Support: This work was supported by the National Eye Institute (National Institutes of Health, Department of Health and Human Services) grants U10EY023529, U10EY023533, and U10EY023521. Support also provided in part by Regeneron, Inc and Allergan, Inc through donation of investigational drug. This work was supported in part by an unrestricted grant from Research to Prevent Blindness, Inc. to the University of Wisconsin Madison Department of Ophthalmology and Visual Sciences and to the Jules Stein Eye Institute and Doheny Eye Institute, Department of Ophthalmology at the University of California Los Angeles. Financial Disclosures: I.U.S. serves as Principal Investigator and Chair of SCORE2, which is funded by the National Eye Institute, and has served as a consultant for Regeneron and F. Hoffmann-La Roche AG and on the Data and Safety Monitoring and Safety Review Committees of clinical trials sponsored by Novartis. M.S.I. reports receiving consultant fees from Clearside, Boehringer Ingelheim, OccuRx, Genentech, Astellas, Allergan, Amgen, Outlook, Novartis, and Regeneron and research support from Astellas, Biogen, Lineage Cell Therapeutics, Novartis, and RegenexBio. All authors attest that they meet the current ICMJE criteria for authorship. The SCORE2 Study Data Coordinating Center Principal Investigator, Dr Paul VanVeldhuisen, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Author Contributions: Study concept and design: I.U.S., P.C.V., M.S.I., B.A.B., N.L.O.; Acquisition, analysis, or interpretation of data: I.U.S., P.C.V., M.S.I., B.A.B., N.L.O.; Drafting of the manuscript: I.U.S., N.L.O., P.C.V.; Critical revision of the manuscript for important intellectual content: M.S.I., B.A.B.; Statistical analysis: N.L.O.: Obtained funding: I.U.S., P.C.V., B.A.B.: Administrative, technical, or material support: P.C.V.; Study supervision: I.U.S., P.C.V., M.S.I., B.A.B.
Publisher Copyright:
© 2022 Elsevier Inc.
PY - 2023/4
Y1 - 2023/4
N2 - Purpose: To investigate the relationship of anti-vascular endothelial growth factor (anti-VEGF) treatment discontinuation with baseline factors and outcomes in eyes treated initially with aflibercept or bevacizumab for macular edema from central or hemiretinal vein occlusion. Design: Long-term follow-up after a randomized clinical trial from 64 US centers. Methods: Analysis included 150 SCORE2 Month 60 completers classified into 3 groups: discontinued treatment early, treated intermittently, and treated continuously. Outcomes included visual acuity (VA) and central subfield thickness (CST). Results: Patients who discontinued treatment early were younger (60.9 years, vs 66.7 and 70.5 for the treated intermittently and treated continuously groups; P = .001), and 17.4% were Black, compared to 19.5% and 4.7% for the treated intermittently and treated continuously groups (P = .006). At Month 60, the discontinued treatment early group had a higher proportion with complete resolution of macular edema (69.6%) than those treated intermittently (15.0%) and treated continuously (15.7%) (P < .001). Least-squares means analyses over follow-up demonstrated that the discontinued treatment early group had a lower mean CST (257 µm) than the treated intermittently (CST = 303 µm, P = .02) and treated continuously (CST = 300 µm, P = .01) groups. Conclusions: Compared to those treated continuously, those who discontinued treatment early were younger and more likely Black. The discontinued treatment early group had a higher proportion with complete resolution of macular edema at Month 60, and a lower mean CST over follow-up, but not better VA, than the treated continuously and treated intermittently groups. Results support the need for continued monitoring and individualized treatment for patients treated with anti-VEGF for macular edema from central or hemiretinal vein occlusion.
AB - Purpose: To investigate the relationship of anti-vascular endothelial growth factor (anti-VEGF) treatment discontinuation with baseline factors and outcomes in eyes treated initially with aflibercept or bevacizumab for macular edema from central or hemiretinal vein occlusion. Design: Long-term follow-up after a randomized clinical trial from 64 US centers. Methods: Analysis included 150 SCORE2 Month 60 completers classified into 3 groups: discontinued treatment early, treated intermittently, and treated continuously. Outcomes included visual acuity (VA) and central subfield thickness (CST). Results: Patients who discontinued treatment early were younger (60.9 years, vs 66.7 and 70.5 for the treated intermittently and treated continuously groups; P = .001), and 17.4% were Black, compared to 19.5% and 4.7% for the treated intermittently and treated continuously groups (P = .006). At Month 60, the discontinued treatment early group had a higher proportion with complete resolution of macular edema (69.6%) than those treated intermittently (15.0%) and treated continuously (15.7%) (P < .001). Least-squares means analyses over follow-up demonstrated that the discontinued treatment early group had a lower mean CST (257 µm) than the treated intermittently (CST = 303 µm, P = .02) and treated continuously (CST = 300 µm, P = .01) groups. Conclusions: Compared to those treated continuously, those who discontinued treatment early were younger and more likely Black. The discontinued treatment early group had a higher proportion with complete resolution of macular edema at Month 60, and a lower mean CST over follow-up, but not better VA, than the treated continuously and treated intermittently groups. Results support the need for continued monitoring and individualized treatment for patients treated with anti-VEGF for macular edema from central or hemiretinal vein occlusion.
UR - http://www.scopus.com/inward/record.url?scp=85147573600&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85147573600&partnerID=8YFLogxK
U2 - 10.1016/j.ajo.2022.12.026
DO - 10.1016/j.ajo.2022.12.026
M3 - Article
C2 - 36584835
AN - SCOPUS:85147573600
SN - 0002-9394
VL - 248
SP - 157
EP - 163
JO - American Journal of Ophthalmology
JF - American Journal of Ophthalmology
ER -